Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
The Journal of Biological Chemistry
|
August 6, 2005
Deconvolution of a complex target using DNA aptamers
Stephen Fitter, Robert James
Obesity Research & Clinical Practice
|
June 20, 2018
Osteopontin in the pathophysiology of obesity: Is Opn a fat cell foe?
Stephen Fitter, Andrew C W Zannettino
Journal of Molecular Endocrinology
|
April 5, 2012
Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
Stephen Fitter, Kate Vandyke, Stan Gronthos, et al.
Stem Cells (Dayton, Ohio)
|
December 28, 2016
The Mesenchymal Precursor Cell Marker Antibody STRO-1 Binds to Cell Surface Heat Shock Cognate 70
Stephen Fitter, Stan Gronthos, Soo Siang Ooi, et al.
Blood
|
November 6, 2009
Dysregulation of bone remodeling by imatinib mesylate
Kate Vandyke, Stephen Fitter, Andrea L Dewar, et al.
Cancer Metastasis Reviews
|
August 5, 2024
Molecular and cellular mechanisms of chemoresistance in paediatric pre-B cell acute lymphoblastic leukaemia
Caleb B Lill, Stephen Fitter, Andrew C W Zannettino, et al.
Leukemia Research
|
January 28, 2015
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
Sally K Martin, Zhen Ying Gan, Stephen Fitter, et al.
Stem Cells and Development
|
December 27, 2007
A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells
Stan Gronthos, Stephen Fitter, Peter Diamond, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 15, 2010
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
Stephen Fitter, Kate Vandyke, Christopher G Schultz, et al.
European Journal of Haematology
|
September 3, 2014
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
Zhen Ying Gan, Stephen Fitter, Kate Vandyke, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
The Journal of Biological Chemistry
|
August 6, 2005
Deconvolution of a complex target using DNA aptamers
Stephen Fitter, Robert James
Obesity Research & Clinical Practice
|
June 20, 2018
Osteopontin in the pathophysiology of obesity: Is Opn a fat cell foe?
Stephen Fitter, Andrew C W Zannettino
Journal of Molecular Endocrinology
|
April 5, 2012
Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
Stephen Fitter, Kate Vandyke, Stan Gronthos, et al.
Stem Cells (Dayton, Ohio)
|
December 28, 2016
The Mesenchymal Precursor Cell Marker Antibody STRO-1 Binds to Cell Surface Heat Shock Cognate 70
Stephen Fitter, Stan Gronthos, Soo Siang Ooi, et al.
Blood
|
November 6, 2009
Dysregulation of bone remodeling by imatinib mesylate
Kate Vandyke, Stephen Fitter, Andrea L Dewar, et al.
Cancer Metastasis Reviews
|
August 5, 2024
Molecular and cellular mechanisms of chemoresistance in paediatric pre-B cell acute lymphoblastic leukaemia
Caleb B Lill, Stephen Fitter, Andrew C W Zannettino, et al.
Leukemia Research
|
January 28, 2015
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
Sally K Martin, Zhen Ying Gan, Stephen Fitter, et al.
Stem Cells and Development
|
December 27, 2007
A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells
Stan Gronthos, Stephen Fitter, Peter Diamond, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 15, 2010
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
Stephen Fitter, Kate Vandyke, Christopher G Schultz, et al.
European Journal of Haematology
|
September 3, 2014
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
Zhen Ying Gan, Stephen Fitter, Kate Vandyke, et al.
Page
of 3